Company says it may be able to get a vaccine approved by regulators as early as the first half of 2021
WEDNESDAY, June 24, 2020 (HealthDay News) — French drugmaker Sanofi has shortened its timeline to get a COVID-19 vaccine on the market.
Sanofi and partner GlaxoSmithKline previously said the earliest they would have a vaccine available would be in the latter half of next year, The New York Times reported.
But Sanofi, which is testing two types of COVID-19 vaccines, said Tuesday that it may be able to get a vaccine approved by regulators as early as the first half of 2021.
However, “such fast-tracking and intense scale of vaccine production is totally unprecedented,” and the future is unknown, Padmini Pillai, an immunologist at MIT, told The Times.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination